We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Certainly some unusual share volumes both here and in the US over the last few days given that the usual daily volumes tend to be quite small. I also wonder about the NASDAQ listing effectiveness. Initially when they listed in the US it looked like they saw NASDAQ being the primary listing but recent insider purchases seem to have been on AIM?
Not today anyway ,son there rea zero trades.
Enigma..over 1 million traded yesterday and nada today..
Well they ain't buying aggressively..
Thanks for that Bronxville - good to see that Amryt seem to be gaining traction with US funds
. Amryt Pharma plc (NASDAQ: AMYT)
Number of Hedge Fund Holders: 8
Amryt Pharma plc (NASDAQ: AMYT) is a United Kingdom-based firm that concentrates on the development and delivery of new drugs to help the patients with rare and orphan diseases. The company has a growing commercial business and invests heavily in research and development. The company makes Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It has operations in the Americas, Europe, and the Middle East. The firm was founded in 2015.
It has a market cap of more than $506 million and posted a revenue of more than $182 million in December 2020, an increase of more than $130 million compared to the previous year. The 52-week share price range of the company stock is $15-$10. Earlier today, it was trading at $13.8. Last year, the company confirmed that its research into a genetic skin disorder had got encouraging results. A request for production of the new treatment will be filed this year. The firm is placed eighth on our list of 10 cheap pharmaceutical stocks for 2021.
The company is also getting the attention of the smart money, as 8 hedge funds tracked by Insider Monkey reported owning stakes in the company at the end of the fourth quarter, up from 4 funds a quarter earlier.
https://finance.yahoo.com/news/10-cheap-pharmaceutical-stocks-2021-132008483.html
Might be a little bit of nibbling across the pond...
A close above $15 could potentially send a strong buy signal
Quite realistic, IMO: with the continual flow of positive RNSes, coupled with similar ones to follow, particularly with the big one for the licence, that target could well be surpassed.
That was yesterday and yet no one gives a fiddlers...Can't understand how management can't generate any interest in Amryt.
Paps..OO is an animal..still holding..3 or 4 spinoffs coming..
Not sure yet about SPC..Think its for another venture but its on my radar..
Its just a shell with a massive share count at the moment.
Amryt Pharma (AMYT) Received its Third Buy in a Row
By Ryan Adsit
Amryt Pharma (AMYT) Received its Third Buy in a Row After Leerink Partners and Maxim Group gave Amryt Pharma (NASDAQ: AMYT) a Buy rating last month, the company received another Buy, this time from Canaccord Genuity. Analyst Michelle Gilson maintained a Buy rating on Amryt Pharma yesterday and set a price target of $40.00. The company’s shares closed last Monday at $14.29.
According to TipRanks.com, Gilson is a 4-star analyst with an average return of 25.2% and a 51.4% success rate. Gilson covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Sigilon Therapeutics, and Travere Therapeutics.
Currently, the analyst consensus on Amryt Pharma is a Strong Buy with an average price target of $33.50, a 136.7% upside from current levels. In a report issued on March 31, Maxim Group also initiated coverage with a Buy rating on the stock with a $27.00 price target.